Background In September, 2012, the UN Commission on Life Saving Commodities (UNCoLSC) outlined a plan to expand availability and access to 13 life saving commodities. We profi le global and country progress against these recommendations between 2012 and 2015.
Introduction
The Every Woman Every Child (EWEC) movement was established in 2010 by the UN Secretary General to address the major health challenges facing women and children around the world. 1 Under this umbrella, the fi rst Global Strategy for Women's and Children's Health was launched as a roadmap to enhance fi nancing, strengthen policy, and improve service delivery for the most vulnerable women and children. It drew attention to the estimated 8 million children dying of preventable causes each year and the 350 000 women dying of complications related to pregnancy and childbirth. 2 Persistent gaps in availability of and access to life saving commodities (medicines and medical devices) were identifi ed as major obstacles to achieving universal basic health care for pregnant women and children. 3 Estimates suggested that, across low-income countries, just a third to half of children received basic drugs to treat childhood diarrhoea and pneumonia (appendix). Similarly, only a third of women received appropriate management for the major causes of maternal death: eclampsia and post-partum haemor rhage. For newer commodities such as implantable contraceptives, zinc for diarrhoea, and intravenous antibiotics for sepsis in newborns, coverage levels were near zero (appendix).
A series of global consultations in 2011 explored strategies to overcome crucial gaps. Barriers included the paucity of aff ordable products and age-appropriate formulations; weak supply chains; inadequate regulatory capacity; and little awareness of where, when, and how to use essential medicines and medical devices. 4 Establish ment of a high-level commission was recommended as a mechanism to synthesise technical evidence and identify innovative actions to rapidly increase availability, access, and rational use of key commodities.
The UN Commission on Life Saving Commodities (UNCoLSC) launched its Report 3 and Implementation Plan 5 in September, 2012, highlighting 13 underused, lowcost, and high-impact commodities across reproductive, maternal, newborn, and child health (RMNCH) that if implemented at scale could make the greatest impact in reducing preventable deaths. The report included ten recommendations for addressing key systemic bottlenecks, including strategies to shape global and local markets; improve regulatory effi ciency; enhance medicine quality and safety; strengthen supply chains; improve health worker performance; augment demand; and stimulate product innovation (fi gure 1). The commodities provided a concrete and actionable focus for eff orts across this continuum, acting as tracers to help identify and address barriers to eff ective intervention delivery.
To advance this agenda, a steering committee was established to draw together stakeholders throughout RMNCH with the aim of enhancing coordination between UN agencies, partner organisations, programmes, and countries. To accelerate implementation, direct technical and fi nancial support was provided to a subset of EWEC countries selected on the basis of being off -track to achieve the Millennium Development Goals for maternal and child survival. Building on International Health Partnership principles, 6 an RMNCH country engagement process was initiated that included a joint, rapid multistakeholder synthesis of the existing plans and subplans relevant to a particular country context; a prioritisation process, based on the RMNCH situation analysis, the burden of disease, and specifi c programmatic and fi nancial gaps across the RMNCH continuum of care; and the commitment of development
Research in context
Evidence before this study Original coverage estimates for the 13 life saving commodities and related reproductive, maternal, newborn, and child health (RMNCH) interventions identifi ed in the UNCoLSC report were generated using the Lives Saved Tool for 49 countries of the world with the lowest income plus India (appendix). Evidence on potential systemic bottlenecks infl uencing coverage such as regulatory hurdles, supply chain weakness, or training gaps are partial and fragmented. This evidence exists in non-standardised formats at the country level and includes policy documents, essential medicines lists, treatment guidelines, health facility assessments, and routine performance monitoring platforms such as health and logistics management information systems.
Added value of this study
This multicountry assessment used the conceptual framework implicit in the UNCoLSC recommendations to systematically track the 13 priority RMNCH commodities across the continuum-from manufacturing through to utilisation and coverage for the post-2012 period. We generated a standardised set of indicators for each recommendation, drawing from the range of best-available data sources outlined above. Country-level bottlenecks that were identifi ed through this process informed the prioritisation and fi nancing of national RMNCH plans. Challenges identifi ed across multiple countries informed evolving global eff orts.
Implications of all the available evidence
Much needs to be done to achieve full implementation of the UNCoLSC recommendations. Coordinated global action will be required to enhance market shaping, secure price reductions, improve regulatory effi ciency, enhance the quality and safety of medicines, and strengthen supply chains. Translation of the latest evidence, tools, and best-practice materials developed through the UNCoLSC and related global initiatives to the country level will require robust and sustained technical assistance. Further harmonisation and alignment of RMNCH monitoring tools and systems is essential. In summary, three main strategies were introduced to further the UNCoLSC recommendations: an RMNCH situation analysis across a range of countries to systematically identify commodity-related and systemsrelated bottlenecks, a country engagement process to provide technical and fi nancial support to national RMNCH plans, and a network of technical resource teams to address global bottlenecks and support country implementation.
This Article reviews progress against these strategies in the 3 years since the UNCoLSC report. With the 2015 launch of the updated Global Strategy for Women's, Children's and Adolescents' Health 7 and new Global Financing Facility, 8 which aim to reduce preventable deaths and improve the quality of life for women, children, and adolescents until 2030, we describe how lessons learned through implementing the UNCoLSC recommendations should inform this ambitious agenda.
Methods

RMNCH situation analysis
We did an RMNCH situation analysis in 12 of the 19 countries that received grants from the RMNCH trust fund in sub-Saharan Africa. The remaining six countries were recent fund recipients, with the timing of the situation analysis at the discretion of national ministries. Between January, 2013, and September, 2015, we collected data from the Democratic Republic of Congo, Cameroon, Ethiopia, Kenya, Malawi, Mali, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, and Zambia.
The situation analysis relied on maximising the use of existing data sources across RMNCH, which included a review of the latest information from national strategic plans, essential medicine and medical device lists, training materials, and other related documents. Where available, we compiled aggregated indicators from nationally representative health facility assessments or health and logistics management information systems, alongside the most recent population-based survey data. We conducted semi-structured interviews with programme managers, procurement and regulatory agencies, and local experts to verify and complement the data sources. Assessments were done in each country over a 1-2 week period by a trained RMNCH facilitator supported by the RMNCH Strategy and Coordination Team in collaboration with ministries, UN country teams, and relevant partners. After each assessment, the RMNCH Strategy and Coordination Team helped with quality assurance procedures, analysis, and content reviews in collaborating organisations.
Before conducting the situation analysis, we undertook a standardisation process to generate a core set of indicators with clear performance thresholds. We used the UNCoLSC framework to inform the choice of indicators, highlighting systemic and commodity-related bottlenecks at each level of the health-care system (table 1) . Standard performance ranges (from 1, weakest, to 5, strongest) were defi ned for each indicator in consultation with the global network of UNCoLSC technical resource teams to show diff erences in systemic and programmatic conditions (appendix). During each country assessment, we compared results of structured question sets with the standard performance cutoff s to generate categorical performance scores (from 1, weakest, to 5, strongest). These scores produced a standard rating that could be compared over time and across countries. A bottleneck is defi ned as moderate-to-weak performance for a particular indicator (see table 1 for indicator-specifi c defi nitions).
We entered results into a relational database (MS Access, Microsoft, 2013), processed the results (R version 3.2.0, 2015), and uploaded the data to a web-based platform. A dashboard was created to provide visual representation of bottlenecks across RMNCH for a single or several countries. Detailed descriptions of methods and performance ratings are provided in the appendix.
RMNCH country engagement process
We monitored country progress in several ways. A representative of the RMNCH Strategy and Coordination Team supported the country engagement process, and formally documented the process using a range of purpose-based tools and systems that articulated the prioritised RMNCH plan, costs, and resource contributions from domestic and partner sources. The UNCoLSC commodity and recommendation area coded budgeted activities from the RMNCH fund grants. Country teams reported 6-monthly progress by use of standard templates, with periodic country visits in many cases.
Progress against global milestones
Global eff orts to advance the UNCoLSC mandate were the responsibility of a network of technical resource teams, who addressed cross-cutting challenges that required coordinated global action, which included priorities and targets outlined in the UNCoLSC 2012 report and a wider range of related activities. About 450 experts from 85 organisations established nine thematic teams: four focusing on commodity areas (one each for the RMNC components), three focusing on systemic areas (global regulation, markets, and policy; supply chain; and demand access and performance); and two cross-cutting themes of digital health and advocacy. An interagency review panel reviewed work plans for each team. Figure 2 profi les each team and related work stream.
Progress against key milestones was documented through a range of methods including: monthly coordination calls, biannual global meetings, an annual workplan reporting against specifi c objectives, and a synthesis of relevant global documents and work products.
Role of the funding source
The funders had no role in the design, conduct, analysis, and writing up of the study. The corresponding author had full access to all data. For more information on the teams and work streams see http://www.lifesaving commodities.org
Results
The proportions of countries with a bottleneck by UNCoLSC recommendation, commodity, and sector of the health-care system are summarised in fi gure 3. For each recom mendation, a bottleneck is defi ned as moderate-to-weak performance on any indicator within a recom mendation. For example, regulatory effi ciency was a bottleneck if the commodity was not on the national Essential Medicines List (EML) in the preferred formulation, treatment guidelines were absent or in complete, or the preferred formulation was not registered in-country or had restricted prescription authority ( coordination, which typically related to poor commodity security strategies. Eight of 12 had insuffi cient regulatory capacity, usually because of poor pharmacovigilance or post-market surveillance systems. We commonly observed commodity-specifi c bottlenecks for regulatory effi ciency, health worker performance and accountability, and supply and awareness. Regulatory bottlenecks were most common in reproductive and neonatal health commodities, and antenatal steroids and emergency contraceptives had regulatory bottlenecks in most countries. All countries had health worker performance gaps: despite having upto-date national curriculum and tools available, only half of facilities had recently trained staff (58%) or tools (53%) to support eff ective service delivery, including job-aids and checklists (appendix).
Supply chain bottlenecks existed in all countries. Although most countries used appropriate forecasting tools, just one of 12 countries assessed had comprehensive logistics management systems to track commodities from central warehouses to service delivery points. National stock-outs were common for female condoms, misoprostol, and dispersible amoxicillin (table 2) . Although data-gaps exist, an average of 40% of health facilities had stock-outs, with child health commodities most available and misoprostol, antenatal steroids, female condoms, and newborn resuscitation equipment out of stock in at least half of facilities. Finally, half of countries still report formal or informal user fees that constrain access to some or all of the 13 commodities. Data was not available for all countries for some indicators. Challenges in presenting the data are outlined in the discussion.
Countries performed better in relation to demand generation, where eight of 12 countries had programmes in place. Nearly all (nine of 11) countries needed all public sector procurements to take place from a goodmanufacturing practice certifi ed manufacturer.
In terms of the RMNCH country engagement process, and to advance the UNCoLSC mandate, the RMNCH Fund committed $175·7 million for 19 countries between Oct 7, 2013, and Aug 15, 2015 . This commitment included an initial wave of eight countries that received support in 2013 and a second group of eleven countries that received support in a phased manner during 2014-15, with the duration of funding extending over a 1-3 year period. All countries in the plan were in sub-Saharan Africa except for Afghanistan, Bangladesh, and Pakistan. $24·9 million (39·0%) of resources were directed to cross-cutting systemstrengthening interventions such as improvement of supply chains, with the remaining balance fairly evenly split between maternal and neonatal joint care ($13·6 million, 8%), family planning ($24·9 millioin, 14%), maternal health ($17·6 million, 10%), neonatal health ($19·5 million, 11%), and child health categories ($31·9 million, 18%). $86·6 m (50·4%) of funds were committed to improve health worker performance and accountability, $53·3 million (30·3%) to strengthen supply chains, and $21·2 million (12·0%) to stimulate demand (fi gure 4). 3·4% of funds were directed to support regulatory effi ciency and quality improvements. Panel 1 provides a summary of achieve ments for an initial wave of eight countries where eff orts have been in progress for at least 18 months.
Global progress against UNCoLSC recommendations was supported through the work of the technical resource teams. All commodities are now formally listed on the WHO EML (panel 2). Global market-shaping eff orts yielded substantial price reductions for implantable contraceptives, and the securing of additional manufacturers created potential competitive price reductions for neonatal resuscitation equipment. Manufacturers were identifi ed for all commodities, including newly listed commodities such as dispersible amoxicillin and chlorhexidine, with manufacturers in south Asia and Africa supported to produce key RMNCH products. Global forecasts were done to estimate manufacturing and procurement needs and a fast-track registration process was established for WHO prequalifi ed commodities. A post-market commodity survey across ten countries suggested that most UNCoLSC commodities, with the exception of oxytocin, were of reasonable quality. Agreements were secured between the Global Alliance for Vaccines and Immunization and UNICEF that allow oxytocin to be included in the vaccine cold-chains. 9 Bestpractice materials were generated for a range of priorities including advocacy, demand generation, supply chain management, digital health, and health worker support (ie, training materials, job aids and checklists). Finally, innovations in product packaging and formulation supported the scale-up of amoxicillin dispersible tablets and misoprostol.
Discussion
The 2015 Millennium Development Goal deadline represented a crucial opportunity to assess progress against key targets and identify remaining gaps. For the Global Strategy for Women's and Children's Health, the world fell short of achieving goals 4 and 5, saving just 2·4 million of the projected 6 million lives of women and children in the past 5 years. 10 As a contributing initiative to this strategy, the UNCoLSC has played a part at the nexus between global systems, countries, and markets to advance more eff ective pricing, procurement, distribution, and delivery of essential commodities. Although major advances have been achieved in implementing its recommendations, a substantial body of work remains. Persistent commodity bottlenecks were common at the country level, including out-of-date EMLs, unregistered commodities, and restrictive guidelines and prescription authority, which limit distribution of commodities where they are needed most. Commodity security strategies were often poorly developed, and capacity to monitor the quality and safety of medicines is scarce. Although most national protocols and training materials were updated, dissemination to peripheral health facilities will need further eff orts. The monitoring and distribution of commodities from national warehouses to service delivery points remains a barrier, with 40% of the 13 priority commodities out of stock at the time of assessment. Fragmented supply chains contribute to these challenges. For example in Kenya, 12 diff erent types of health commodities are provided by at least 18 donor organisations, procured by 13 agencies, sent to fi ve warehouses, and delivered through seven supply chains. 11 The UNCoLSC experience suggests that countries opted to fi nance a balanced set of RMNCH priorities-from focused eff orts to scale up implantable con traceptives to cross-cutting eff orts to strengthen supply chains. Commodity procurement was de-emphasised, potentially because the 13 UNCoLSC commodities were low-cost and could be sustainably procured through national systems. Although frequent regulatory and quality assurance bottlenecks were identifi ed at the country-level, they were not often prioritised, which suggests additional guidance and technical support could be appropriate.
Most of the global milestones outlined in the original UNCoLSC Report and Implementation Plan have been achieved or are nearing completion. Key areas of progress include listing all commodities on the WHO EML; securing price reductions for implantable contraceptives; establishing a fast-track system to accelerate product registration; and generating means and materials to support advocacy, demand generation, and health worker training. However, progress is slower in other areas. National regulatory systems remain complex and ineffi cient, creating disincentives for manufacturers to register commodities with low profi t margins. Eff orts to streamline and harmonise systems between countries, such as the African Medicines Regulatory Harmonization Programme, are crucial. 12 Commodity procurement is often hindered by being out of line with domestic budget cycles, leading to national stock-outs. 13 The feasibility of a revolving fund to support commodity procurement is under exploration. Finally, mechanisms to support quality assurance for essential medicines will require additional technical support from the global and regional levels. 14, 15 The process of documenting the country status in relation to UNCoLSC recommendations highlighted often overlooked implementation barriers, but several limitations and information gaps are evident. First, the sub-Saharan African countries assessed might not adequately represent challenges experienced elsewhere on the continent or in other regions. Second, although eff orts were made to capture the most up-to-date information since 2012, recent gains might not be adequately profi led. Third, existing data sources in several areas are inadequate. For example, coverage data exist for child health and family planning (with the exception of emergency contraception), but there are few standard information sources to document delivery of maternal and neonatal interventions and the quality of care provided. Global eff orts are underway to address these gaps. 16 Fourth, country bottleneck identifi cation depended upon the generation of categorical variables from nonstandard and sometimes qualitative data collected by diff erent enumerators. Despite the use of expertly defi ned performance thresholds to generate these variables, this process might be subject to interpretation and bias. Finally, although this assessment provides a snapshot of commodities and related systems, periodic updating will be essential to track change over time.
Lessons learned from implementation of the UNCoLSC agenda carry important implications for the updated Global Strategy for Women's, Children's and Adolescents' Health. The fi rst priority is securing fi nancing needed to support country plans. Estimates suggest an additional $28-30 billion per year is needed to close the gap across 75 high-priority countries. 7 Under the umbrella of the new Global Financing Facility, a more sustainable mix of grant and loan-based support is envisioned to be channelled to countries based on prioritised reproductive, maternal, neonatal, child, and adolescent health (RMNCAH) investment cases. The second priority is the need for commodity perspectives to inform the development and monitoring of investment cases, and national plans to achieve the targets outlined in the updated Global Strategy. The commodity lens has provided a useful and actionable focus for identifying and addressing key bottlenecks; use of standard metrics to track commodity fl ow highlights crucial gaps. Eff orts to simplify and standardise the monitoring of country plans and investment cases, drawing from the UNCoLSC experience and other initiatives such as Countdown 2015, are essential. 17 Finally, the unfi nished components of the UNCoLSC mandate have the potential to inform an agenda for the socalled global public good, where coordinated eff orts at the global and regional levels provide complementary support to country implementation. This agenda should include market-shaping eff orts to secure price reductions beyond the 13 commodities; the establishment of fi nancing mechanisms to underwrite timely domestic commodity procurement; eff orts to improve regulatory effi ciency through establishing product standards, harmonisation of guidelines, and support for joint inspections; and mechanisms to foster procurement of quality products, enhance post-market surveillance, and strengthen pharmacovigilance. Addressing supply chain gaps will require global eff orts to reduce fragmentation and country action to improve forecasting, logistics management, and distribution. Finally, robust and sustained technical support should be made available to strengthen RMNCAH investment cases, ease country access to the latest evidence and best-practice materials, and enhance south-south exchanges and regional learning to support the implementation of nationally defi ned priorities.
